This inventor holds 3 USPTO granted patents. Top assignee: Quark Biotech, Inc.. Active years: 2002-2006.
Data source: USPTO (United States Patent and Trademark Office) public patent records. Weekly synchronization. How IDiyas builds this profile
Company Filing History:
Years Active: 2002-2006
Title: Innovator Shlomit Gilad: Pioneering Advances in Antisense RNA Technology
Introduction
Shlomit Gilad, an accomplished inventor based in Gedera, Israel, has made significant contributions to the field of biotechnology, particularly in the study and manipulation of natural antisense messenger RNA. With a total of three patents to her name, she is advancing the understanding of RNA interactions and their applications in genetic research.
Latest Patents
Among her latest innovations is a groundbreaking method for the enrichment of natural antisense mRNA. This patented method involves hybridization of complementary DNA (cDNA) obtained from sense RNA with cDNA derived from antisense RNA. The subsequent treatment of the resulting sense-antisense hybrid DNA molecule with DNA polymerase enables the generation of a natural antisense library through the cloning of these hybrid DNA molecules in a vector. This innovative approach not only enhances the understanding of RNA functionality but also paves the way for novel therapeutic strategies.
Career Highlights
Shlomit Gilad currently works at Quark Biotech, Inc., where she applies her knowledge and expertise to further develop cutting-edge biotechnological solutions. Her role at the company showcases her commitment to advancing scientific research and innovation.
Collaborations
Working alongside talented colleagues such as Paz Einat and Avital Grossman, Shlomit fosters a collaborative environment that encourages the exchange of ideas and expertise. These partnerships enhance the potential for new discoveries in the field of biotech.
Conclusion
In conclusion, Shlomit Gilad’s work and patents serve as an inspiration within the biotechnology community. Her innovative methods for enriching natural antisense mRNA not only contribute to the academic understanding of RNA interactions but also hold promise for future therapeutic development. As she continues her efforts at Quark Biotech, Inc., the scientific world eagerly anticipates the fruits of her ongoing research and collaborations.
Data source: USPTO (United States Patent and Trademark Office) public patent records. Weekly synchronization. How IDiyas builds this profile